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Cardiac Function and Heart Failure
1145-117 Reduction in Regional Myocardial Function Is 
Associated With Concentric Left Ventricular 
Remodeling: Multi-Ethnic Study of Atherosclerosis
Boaz D. Rosen, Thor Edvardsen, David Bluemke, Li Pen, Michael Jerosch-Herold, Sinha 
Shantanu, Shenghan Lai, Joao Lima, Johns Hopkins Hospital, Baltimore, MD
Background: Left ventricular hypertrophy is a risk factor for heart failure, but the transition
from regional myocardial dysfunction, compensatory remodeling and global dysfunction
has not been thoroughly clarified. Therefore, we investigated the association between LV
remodeling and regional LV function expressed as peak systolic circumferential strain
(Ecc) in participants of the Multi-Ethnic Study of Atherosclerosis (MESA).
Methods: Peak Ecc from 441 tagged MR studies was determined by Harmonic Phase
(HARP) tool, and its relationship with the degree of concentric remodeling expressed by
LV mass/ end diastolic volume (M/V) ratio was studied. Regions were defined by coro-
nary territories.
Results: In both genders, reduced strain was seen in the highest quartile of M/V ratio
when compared to lower quartiles (-13.2 vs -15.3, p<0.01). This decrease was regionally
nonuniform and was more pronounced in the left anterior descending (LAD) region (fig-
ure, *p<0.01). However, it was statistically significant in all regions. Decrease from the
first three quartiles to the fourth quartile in LAD, right (RCA)and left circumflex (LCX)
regions was 15.3%, 12.3% 10.3%, respectively (p<0.05 for all regions).
Conclusion: Concentric remodeling is associated with reduced systolic regional function
in asymptomatic individuals. Decrease in function is more prominent in the LAD territory
but is also present in the RCA and LCX regions. It may reflect transition from compensa-
tory remodeling to myocardial failure.
. 
1145-118 Torasemide Inhibits Transcardiac Extraction of 
Aldosterone in Patients With Congestive Heart Failure
Takayoshi Tsutamoto, Chitose Ishikawa, Keijin Ohno, Hiroshi Sakai, Atsuyuki Wada, 
Masato Ohnishi, Minoru Horie, Shiga University of Medical Science, Otsu, Japan
Background. We reported that mineralocorticoid receptor antagonist spironolactone
inhibits the transcardiac extraction of aldosterone (ALD) in patients with congestive heart
failure (CHF). In the TORIC (TORasemide In patients with Congestive heart failure in
NYHA class II and III) study, torasemide had more beneficial effect on mortality and mor-
bidity of CHF patients than furosemide. However, the mechanism of the beneficial effect
of torasemide remains unknown. Method. To evaluate whether the torasemide has an
aldosterone (ALD) receptor antagonist, we studied 50 CHF patients who had been ran-
domly administered furosemide (n=25) or torasemide (n=25). Patients who received
spironolactone were excluded in this study. Results. There was no difference of patients
characteristics and other treatments between the two groups. There was no difference of
NYHA functinal class, left ventricular ejection fraction (35±9 vs. 33±10%), or plasma lev-
els of ALD and brain natriuretic peptide (BNP) (372±91 vs. 315±74 pg/mL) in the aortic
root (AO) between the two groups. In the furosemide group, plasma ALD was signifi-
cantly lower in the coronary sinus (CS) than in the AO (96±11 vs. 75±12 pg/mL,
p<0.001), suggesting that ALD is extracted through the heart. In contrast, there was no
difference of plasma ALD between the AO and CS in the torasemide group (83±11 vs.
78±12 pg/mL, p=0.17) and the transcardiac gradient of ALD[ALD (AO-CS)] was signifi-
cantly lower in the torasemide group than the furosemide group (4.6±3 vs. 16±4 pg/mL,
p<0.05), suggesting that the extraction of ALD through the heart is inhibited by
torasemide. In addition, plasma procollagen type III aminoterminal peptide, a biochemi-
cal marker of fibrosis, level in the CS is significantly lower in in the torasemide group than
the furosemide group (0.5±0.03 vs. 0.65±0.08 U/mL, p<0.05). Conclusion. These find-
ings suggest that torasemide has an ALD receptor antagonist in the failing heart in
patients with CHF.
1145-119 Tissue Inhibitor of Matrix Metalloproteinase-1 Is a 
Marker of Left Ventricular Diastolic Dysfunction in 
Diabetic Heart Disease
Sern H. Lim, Muzahir H. Tayebjee, Robert J. MacFadyen, Gregory Y. Lip, Haemostasis, 
Thrombosis and Vascular Biology Unit, City Hospital, Birmingham, United Kingdom
Background: The high prevalence of diastolic dysfunction in diabetes may be related to
abnormal cardiac extracellular matrix composition, regulated by matrix metalloprotein-
ases (MMP) and tissue inhibitors of metalloproteinases (TIMP). We hypothesised that
plasma MMP-9, TIMP-1 & -2 are related to diastolic dysfunction in patients with diabetes.
Methods: We measured plasma MMP-9, TIMP-1 & -2 by ELISA in 56 patients with dia-
betes and 16 comparable controls. Early (E) and atrial (A) diastolic mitral inflow velocity
was measured with pulse wave Doppler and early mitral annular velocity (E’), an index of
diastolic relaxation, with tissue Doppler on transthoracic echocardiogram. The ratio of E
to A (E/A) and E to E' (E/E', an index of left ventricular filling pressure) were derived from
these measurements.
Results: Patients with diabetes had lower E’, higher E/E’ ratio and higher TIMP-1 levels
(Table). There was no significant difference in E/A ratio, MMP-9 and TIMP-2 levels
between patients and controls. E’ (r = -0.31, p=0.02) but not the ratio of E/E’ (p=0.061)
correlated negatively with TIMP-1. There were no significant correlations between TIMP-
1 with age, systolic or diastolic blood pressure and HbA1c. TIMP-1 remained a predictor
of E’ on multivariate regression analysis (p=0.002).
Conclusion: In diabetes, raised circulating levels of TIMP-1 is associated with abnormal
diastolic function. This suggests that TIMP-1 may be involved in abnormal cardiac extra-
cellular matrix turnover in diabetes.
1145-120 Left Ventricular Mass Reduction in Type 1 Diabetes 
Mellitus
Larry A. Weinrauch, John A. D'Elia, Ray E. Gleason, Andrew Burger, Annette Lee, Joslin 
Diabetes Center, Boston, MA, Beth Israel Deaconess Medical Center, Boston, MA
Background: Improvement in glucose control of patients with type 1diabetes (DM1) has
been demonstrated to blunt the progression of microvascular complications (retinopathy,
nephropathy). A relationship between renal dysfunction, level of advanced glycated end
products (AGE) and microvascular complications has recently been shown. Last year we
reported that a fall in HbA1c was also associated with a reduction in left ventricular mass
(LVM) and LV septal thickness (LVS). We now postulate that reduction of LVM and AGE is
less likely to occur when renal dysfunction progresses.
Method: 17 DM1 patients (pts) with proteinuria were followed for 12 months on an inten-
sive glycemia/hypertension control program with repeated ambulatory blood pressure
monitoring, echocardiogram, serum creatinine, creatinine clearance and AGE.
Results: Of the 17, ten pts decreased LV mass (LVM) >= 20 g (mean = 46 ± 7 g), during
the study, 7 did not (mean increase = 20 ± 12 g, p = 0.0002). These two LVM groups dif-
fered with respect to change in AGE (p = 0.01), but not HbA1c. MAP (94, 107 baseline, p
= 0.0045; 98, 103 12 months, p = ns; delta 4.45, -3.79, p = 0.0186) was similar in all
groups at the end of the study. Eight pts decreased septal (LVS) thickness >= 1mm dur-
ing the study, 9 did not (-1.75 ± 0.25 vs. 0.56 ± 0.18, p = 0.0001). These two LVS groups
differed with respect to change in HbA1c (p < 0.05), but not in AGE or MAP.
The 10 pts with a decrease in LVM maintained creatinine clearance (Ccreat) at 63 ml/
min. The 7 pts without a decrease in LVM changed Ccreat from 54 to 40 (p < 0.02). The 8
pts with decreased LVS changed Ccreat from 65 to 57 ml/min. The 9 pts without a
decrease in LVS changed Ccreat from 54 to 50 ml/min (p = ns)
Conclusion: Decreases in LVM and LVS as a result of glycemic and blood pressure con-
trol appear to be related to preservation of renal function in DM1. In a total group of
patients that diminished LVM with glycemic and blood pressure control, we noted that
LVM decreased preferentially in pts with stable renal function.
1145-121 Prognostic Value of Plasma Erythropoietin on Mortality 
in Patients With Chronic Heart Failure
Peter Van der Meer, Adriaan A. Voors, Erik Lipsic, Tom D. Smilde, Wiek H. Van Gilst, Dirk 
J. Van Veldhuisen, University Hospital Groningen, Groningen, The Netherlands, 
University of Groningen, Groningen, The Netherlands
Background
Anemia is common and is associated with mortality in chronic heart failure (CHF). Eryth-
ropoietin (EPO) is a hematopoietic growth factor, upregulated in anemic conditions. Its
prognostic value in CHF patients is unknown.
Methods and results
In 74 patients with CHF (age 60±7 years, Left Ventricular Ejection Fraction (LVEF)
0.32±0.01, peak oxygen consumption (VO2) 19.1±0.6, (mean±SEM) and in 15 control
patients, plasma concentrations of EPO were prospectively assessed. During a mean fol-
low-up of 2.6 years, 22 patients (30%) died. Anemia (hemoglobin levels <12 g/dl) was
present in 12.9% of the patients. We observed only a mild inverse correlation between
the logarithm of EPO log(EPO) and hemoglobin levels (r2=0.08, p = 0.02), which was
much more pronounced in the control group r2=0.44, p=0.007). There was a significant
association between log(EPO) and BNP levels (r2=0.27, p < 0.001). Multivariate analysis
showed that plasma EPO (p=0.02), hemoglobin levels (p=0.002) and age (p=0.02) were
independent predictors of survival in this CHF population.
Conclusion
Table: data as mean ± SD or median (IQR)
Patients
(n=56)
Controls
(n=16)
P value
Age (years)
SBP (mmHg)
DBP (mmHg)
HbA1c (%)
E’ (cm/s)
E/A
E/E’
MMP-9 (ng/ml)
TIMP-1 (ng/ml)
TIMP-2 (ng/ml)
68 ± 6
139 ± 17
76 ± 9
7.6 ± 1.5
0.07 ± 0.01
0.87 ± 0.19
10.8 ± 1.2
45 (32 – 50)
450 (370 – 525)
140 (140 – 185)
65 ± 7
128 ± 16
78 ± 8
5.5 ± 0.2
0.09 ± 0.02
0.89 ± 0.15
9.3 ± 1.9
37 (31 – 42)
380 (300 – 479)
150 (130 – 178)
0.23
0.02
0.63
<0.001
0.007
0.21
0.002
0.48
0.037
0.78
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Elevated plasma EPO levels are related to the severity of CHF and are associated with
an impaired prognosis independent of hemoglobin levels and other established markers
of CHF severity. Furthermore, EPO levels poorly correlate with the Hb levels, in contrast
to the control group. The observed blunted EPO response to anemia in CHF needs fur-
ther study. 
1145-122 Prevention of Atrial Fibrillation in Symptomatic Chronic 
Heart Failure by Candesartan: Results From CHARM
Karl Swedberg, Marc Pfeffer, Alain Cohen-Solal, Anique Ducharme, Christopher 
Granger, Eric Michelson, John McMurray, James Young, Salim Yusuf, Sahlgrenska 
University Hospital/Östra, Göteborg, Sweden, Brigham & Women's Hospital, Boston, MA
Background: Atrial fibrillation (AF) is claimed to be associated with increased risk in
chronic heart failure (CHF). Small studies have suggested an effect of angiotensin-1
receptor blockers (ARB) on the incidence of AF. In the 3 CHARM (Candesartan in Heart
failure Assessment of Reduction in Mortality and morbidity trial) trials the effect of the
ARB, candesartan, was evaluated on cardiovascular mortality and morbidity in a broad
spectrum of patients with symptomatic CHF. We have assessed the impact of cande-
sartan compared with placebo on development of AF in CHARM.
Methods: In CHARM Overall 7601 patients with symptomatic CHF were randomized to
candesartan (target dose 32 mg, mean dose 24 mg) or placebo (including n=4576 with
LVEF<40% and n=3025 with LVEF>40%). Major exclusions included S-creatinine > 265
umol/l, S-potassium>5.5 mmol/l and symptomatic hypotension. Major outcomes
included: all-cause mortality, CV mortality and CV death or CHF hospitalizations. Mean
follow-up was 38 months. A prespecified Cox regression adjustment was performed
using baseline covariate variables. These variables included almost all baseline demo-
graphics collected.
Results: 5518 (72.6 %) pat. did not have AF at baseline. In the candesartan group, inci-
dence of new AF was 179 pat. (6.5%) compared to 216 pat. (7.9%) in the placebo group
(Odds ratio, OR= 0.82 (95% CI 0.67-1.00; p=0.054). After adjustment for the pre-speci-
fied baseline co-variates OR=0.81 (95% CI 0.66-1.00; p=0.048). There was no heteroge-
neity between the three component trials (p=0.50).
Conclusions: The ARB, candesartan, can prevent the development of AF in symptomatic
CHF.
1145-123 Inadequate Perception of Heart Failure Is Associated 
With Underuse of Diagnostic and Therapeutic 
Strategies in Heart Failure by the Primary Care 
Physician: Results From SHAPE, a Major European 
Survey
Willem J. Remme, Charles Cline, Alain Cohen Solal, Rainer Dietz, Richard Hobbs, Karen 
Keukelaar, Jose Lopez Sendon, Cezar Macarie, John McMurray, Christina Opasich, 
Bernhard Rauch, Witold Ruzyllo, Faiez Zannad, Sticares Cardiovascular Research 
Foundation, Rhoon, The Netherlands
Background: Novel diagnostic and therapeutic strategies in heart failure (HF) signifi-
cantly improve prognosis and attenuate disease progression, thereby reducing morbidity.
In Europe, the majority of HF patients are cared for by primary care physicians (PCPs). It
is unknown to what extent European PCPs perceive these new developments and apply
them to clinical practice.
Methods: SHAPE (Study of Heart failure Awareness and Perception in Europe)
assessed awareness and perception of HF in 3000 randomly selected PCPs in France,
Germany, Italy, Netherlands, Poland, Romania, Spain, Sweden and UK. Native language
questionnaires were used, consisting of 31 questions covering epidemiology, aetiology
and diagnostic and therapeutic strategies in HF.
Results: HF prevalence was clearly underestimated, 82% of PCPs thought it 1% or less.
PCPs would diagnose HF based on signs and symptoms alone in 75% of cases, and
22% believed the response to diuretics necessary to confirm the diagnosis. Although
more than 90% would regularly prescribe an ACE inhibitor (ACEi) plus diuretic, 39%
would always start treatment with a diuretic. When a patient would remain symptomatic
despite optimal ACEi and a diuretic, only 34% would add a beta-blocker. More would pre-
scribe digoxin or spironolactone. Target doses of ACEi and beta-blockade as indicated in
HF treatment guidelines would only be reached by 18-30% and 7-29% of PCPs, resp.
Beta-blockade was considered of high risk for worsening HF (38%), hypotension (34%),
heart block (61%) and bronchospasm (71%), and a reason to stop treatment. ACEi was
believed to lead to renal impairment (88%) and hypotension (94%), reasons to stop treat-
ment, but also to worsening HF by 35%. In contrast, 1/3 of PCPs did not consider angio-
edema a potential risk. As regards the benefit of new HF treatment, 69% voted for
improved quality of life, rather than survival. Finally, 68% incorrectly estimated the per-
centage of overall health care costs for HF as high as 5 - 25%.
Conclusion: The European PCPs perception of all aspects of HF is clearly inadequate.
Under-use of guideline-recommended diagnostic and therapeutic strategies indicates the
need for education of these essential health care providers.
1145-124 Trends and Outcomes in Long-Term Use of 
Anticoagulants on Congestive Heart Failure Patients: 
1999-2002
Allan Anderson, Phillip Brown, Aaron Kugelmass, Lynn Tarkington, Salvatore Battaglia, 
April Simon, Steven Culler, Edmund Becker, Emory University, Atlanta, GA, HCA, Inc., 
Nashville, TN
Background: CHF is an increasing patient population in the United States. Thrombo-
genic events which occur in the presence of CHF can be devastating. Long-term use of
anticoagulants in CHF patients has been shown to decrease thrmobotic events.
Methods: All patients with a primary diagnosis of CHF (DRG 127) from the HCA
Casemix Database; a dataset of all consecutive patients discharged from 191 HCA hos-
pitals treating CHF over the period January 1999 through December 2002. A total of
156,564 CHF admissions were analyzed. Co-morbid conditions, procedures, complica-
tions, and outcome variables were defined through ICD-9 coding. Odds ratios for five in-
hospital outcomes: death, ARF, cardiac complications, neurological complication, and
discharge home were estimated using logistic regression adjusting for age, gender, and
17 other patient co-morbid and procedural characteristics.
Results: Over 4 years, the mean age for CHF patients declined from 76 to 73 years of
age with males representing between 45% and 46% of the CHF population. The long-
term use of anticoagulation grew 56% over the 4-year period from 3.2% to 5.4% in
patients hospitalized with a primary diagnosis of CHF. Logistic regression demonstrated
that CHF patients on long-term anti-coagulation have lower mortality - 42% (p<0.001),
lower rates of ARF - 36% (p<0.001), and are more likely to be discharged home 37%
(p<0.001) than those not on long-term anticoagulation.
Conclusions: Long-term anticoagulation use in community based CHF management
has increased significantly (56%) from 1999-2002. Long-term use of anticoagulation was
associated with a significant decrease in incidence of in-hospital mortality and ARF. Addi-
tionally, CHF patients who were anticoagulated are significantly more likely to be dis-
charged home.
1145-125 The Role of Sildenafil in Establishing Pulmonary 
Arterial Reactivity in Advanced Heart Failure
Jamshid Alaeddini, Patricia A. Uber, Robert L. Scott, Myung H. Park, Hector O. Ventura, 
Mandeep R. Mehra, Ochsner Clinic Foundation, New Orleans, LA
Background: In patients with advanced heart failure, it is essential to document revers-
ibility of pulmonary hypertension (PH ) as part of pre-operative evaluation for cardiac
transplantation as well as to ascertain pharmacological responsiveness. Sildenafil, a
specific phosphodiesterase-5 inhibitor, has been shown to decrease pulmonary vascular
resistance (PVR) and might serve as an important agent in evaluating heart failure
related secondary PH.
Methods: We evaluated twelve consecutive patients (7 men, age 50 ±14 years, 6 non-
ischemic cardiomyopathy, left ventricular ejection fraction 25±15%) with chronic heart
failure and PH. Patients received oral doses of sildenafil 25 mg – 50 mg (upto 3 doses 8
hours apart. Their baseline medications included milrinone (n=7), dobutamine (n=7), and
nitroprusside (n=1) Nesiritide (n=3). All patients had a pulmonary artery catheter for inva-
sive hemodynamic measurements and serial alterations in pulmonary artery pressures
were assessed
Result: Hemodynamic changes were seen within 2 hours after the first dose of oral
sildenafil. Within 2 hours after the first dose of oral sildenafil systolic pulmonary artery
pressure (PAP) declined from 71±20 to 53±26 mmHg, Diastolic PAP from 29±9 to19±9
mmHg, pulmonary artery mean pressure from 43±12 to 31±14 mmHg, pulmonary wedge
pressure from 25±7 to 18±6 mmHg, PVR from 302±115 to 193±81 dyne. s/cm5, and sys-
temic vascular resistance from 1457±856 to 1095±694 dyne . s/cm5 (p<0.05 for all). Car-
diac index increased from 2.4±0.9 to 2.8±1.0 L/m2 per minute (p<0.05). All patients but
one had a positive hemodynamic response to oral sildenafil (more than 20% reduction in
mean PAP or PVR). There was no clinically significant drop in the blood pressure (pre-
sildenafil: systolic 109±20; diastolic 62±11 vs 106±22; 59±10 mmHg after drug adminis-
tration, p=NS). Patients did not experience any adverse effect associated with adminis-
tration of sildenafil.
Conclusion: Oral sildenafil appears to be an effective and safe agent for evaluation of
reactivity of PH. The pulmonary antihypertensive effects demonstrate selectivity for the
pulmonary vasculature with maintenance of systemic blood pressure.
